Triple Quadrupole/Linear Ion Trap LC-MS/MS for LPI
用于 LPI 的三重四极杆/线性离子阱 LC-MS/MS
基本信息
- 批准号:7796306
- 负责人:
- 金额:$ 48.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsAreaBehavior TherapyBiologicalBiological MarkersCardiovascular systemCenters of Research ExcellenceChronic DiseaseComplementary MedicineComplementary and alternative medicineComplexCore FacilityCultured CellsDataDetectionDietDietary ComponentDiseaseEducationEnvironmental HealthEquipmentFacultyFundingGoalsHealth Care CostsHome environmentHumanHybridsInflammationInstitutesInternationalIonsLaboratoriesLifeLife StyleLinear Accelerator Radiotherapy SystemsLipid PeroxidationMalignant NeoplasmsMass Spectrum AnalysisMeasuresMetabolic DiseasesMicronutrientsMitochondriaModelingMolecularNational Center for Complementary and Alternative MedicineNeurodegenerative DisordersOregonOxidative StressPersonsPlasmaPreparationPreventionPrincipal InvestigatorPublic HealthResearchResearch PersonnelS-1 Antimetabolite agentSafetySamplingScanningScienceSiteSpeedStressSystemUnited StatesUniversitiesUrineVitaminsage relatedantioxidant therapydesigndietary antioxidanthealthy aginghuman diseaseimprovedinstrumentliquid chromatography mass spectrometrymass spectrometermemberoperationoxidative damagepressurepreventprogramspublic health relevancesuccesstransmission process
项目摘要
DESCRIPTION (provided by applicant): The specific aim of this application is to strengthen our programs on oxidative stress-, inflammation- and age-related diseases by acquiring an Applied Biosystems 5500 QTrap Liquid Chromatography-Mass Spectrometry System (5500 QTrap LC-MS/MS) for the sensitive detection, identification, and quantification of small biomolecules in complex biological matrices. This sophisticated instrument will support NIH-funded research directed by 12 Principal Investigators of the Linus Pauling Institute (LPI) at Oregon State University (OSU). LPI is home for a program project, "Center of Excellence for Research on Complementary and Alternative Medicine (CAM) Antioxidant Therapies (CERCAT)," involving several faculty members. It was one of the first two Centers of Excellence for Research on CAM (CERC) funded by NCCAM in 2003; in 2008 it was competitively renewed. The LPI has established itself as a national and international leader in research and education on micronutrients and antioxidants, and is one of a few research centers in the US to focus entirely on increasing human "healthspan" - the period of a person's life during which they are generally healthy and free from serious or chronic illness - by dietary, lifestyle, and complementary medicine means. The acquisition of the 5500 QTrap LC-MS/MS instrument will primarily benefit a main user group of eight LPI principal investigators, who are also affiliated with either the NIH-supported Environmental Health Sciences Center (EHSC) and/or the Center for Healthy Aging Research (CHAR) at OSU. The 5500 QTrap will be sited in the Oxidative Nitrative Stress Laboratory (ONSL), one of two LPI core facilities. In 2011, the ONSL will move to the new Linus Pauling Science Center (LPSC). The ONSL in LPSC has been designed as a facility for mass spectrometry complete with a dedicated biological safety level-2 (BSL-2) sample preparation area. Thus, the ONSL will provide the necessary facilities for operation of the requested 5500 QTrap. This LC-MS/MS system has the combined capabilities of a triple quadrupole MS and a linear ion trap MS instrument. The 5500 model has a QJet2 ion guide which operates at higher pressure to increase ion transmission by collisional cooling and focusing of ions. A major improvement is the new Linear Accelerator Trap which shows superior extraction efficiency and resolving power at fast scan speeds of up to 20,000 Th s-1. These combined improvements result in significant gain in sensitivity compared with our current equipment. These unique capabilities will be of great benefit to quantitation and characterization of lipid peroxidation products and metabolites, as well as vitamins and their metabolites in biological samples including human plasma or urine, cultured cells and mitochondria. Data generated using this new instrument will significantly enable the success of this large group of NIH-funded investigators.
PUBLIC HEALTH RELEVANCE: Researchers in the Linus Pauling Institute at Oregon State University investigate the mechanisms by which oxidative stress and inflammation affect disease initiation and progression at the molecular, cellular, and whole body level, and how dietary antioxidant and anti-inflammatory factors can be used in the prevention and treatment of human diseases, including cardiovascular and metabolic diseases, cancer, and neurodegenerative diseases. The specific aim of this application is to strengthen our programs by acquiring a sophisticated instrument called a "hybrid triple quadrupole/linear ion trap mass spectrometer" that will allow us to analyze biomarkers of oxidative damage, inflammation, and disease and measure dietary components in human plasma and urine. The ultimate goal of these studies is to help prevent and treat human diseases by targeted diet and lifestyle modifications, thereby extending healthspan, improving personal and public health, and reducing health care costs in the United States.
描述(由申请人提供):本申请的具体目的是通过获得Applied Biosystems 5500 QTrap液相色谱-质谱系统(5500 QTrap LC-MS/MS)来加强我们在氧化应激、炎症和年龄相关疾病方面的项目,该系统用于复杂生物基质中小生物分子的灵敏检测、鉴定和定量。这个复杂的仪器将支持NIH资助的研究,该研究由俄勒冈州州立大学(OSU)的莱纳斯鲍林研究所(LPI)的12名首席研究员指导。LPI是一个计划项目的所在地,“补充和替代医学(CAM)抗氧化疗法(CERCAT)卓越研究中心”,涉及几名教职员工。它是2003年由NCCAM资助的前两个CAM研究卓越中心(CERC)之一; 2008年,它被竞争性地更新。LPI已成为微量营养素和抗氧化剂研究和教育的国家和国际领导者,并且是美国少数几个完全专注于增加人类“健康寿命”的研究中心之一-一个人的一生中,他们通常是健康的,没有严重或慢性疾病-通过饮食,生活方式和补充医学手段。5500 QTrap LC-MS/MS仪器的收购将主要惠及由八名LPI首席研究员组成的主要用户群体,他们也隶属于NIH支持的环境健康科学中心(EHSC)和/或健康老龄化研究中心(CHAR)在俄勒冈州立大学。5500 QTrap将位于氧化硝化应力实验室(ONSL),LPI的两个核心设施之一。2011年,ONSL将搬到新的莱纳斯鲍林科学中心(LPSC)。LPSC中的ONSL被设计为质谱分析设施,配有专用的生物安全等级2(BSL-2)样品制备区。因此,ONSL将为要求的5500 QTrap的运行提供必要的设施。该LC-MS/MS系统具有三重四极杆MS和线性离子阱MS仪器的组合功能。5500型号有一个QJet 2离子导向器,它在更高的压力下工作,通过碰撞冷却和离子聚焦来增加离子传输。一个主要的改进是新的线性加速器陷阱,它显示出优越的上级提取效率和解决能力,在快速扫描速度高达20,000 Th s-1。与我们目前的设备相比,这些综合改进导致灵敏度显著提高。这些独特的能力将非常有利于定量和表征脂质过氧化产物和代谢物,以及生物样品中的维生素及其代谢物,包括人血浆或尿液,培养细胞和线粒体。使用这种新仪器生成的数据将大大促进NIH资助的研究人员的成功。
公共卫生相关性:俄勒冈州州立大学莱纳斯鲍林研究所的研究人员研究了氧化应激和炎症在分子、细胞和全身水平上影响疾病发生和发展的机制,以及饮食抗氧化剂和抗炎因子如何用于预防和治疗人类疾病,包括心血管和代谢疾病、癌症和神经退行性疾病。这项申请的具体目的是通过获得一种名为“混合三重四极杆/线性离子阱质谱仪”的复杂仪器来加强我们的计划,该仪器将使我们能够分析氧化损伤,炎症和疾病的生物标志物,并测量人体血浆和尿液中的饮食成分。这些研究的最终目标是通过有针对性的饮食和生活方式改变来帮助预防和治疗人类疾病,从而延长健康寿命,改善个人和公共健康,并降低美国的医疗保健成本。
项目成果
期刊论文数量(24)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Phytochemical characterization and bioactivity toward breast cancer cells of unhydrolyzed and acid-hydrolyzed extracts of Fagonia indica.
- DOI:10.1177/1934578x221109426
- 发表时间:2022-07
- 期刊:
- 影响因子:1.8
- 作者:Miranda, Cristobal L.;Kumbi, Yadano;Wu, Wenbin;Lee, Hyi-Seung;Reed, Ralph L.;Stevens, Jan F.
- 通讯作者:Stevens, Jan F.
Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPARγ.
- DOI:10.7554/elife.66398
- 发表时间:2021-06-15
- 期刊:
- 影响因子:7.7
- 作者:Zhang Y;Bobe G;Miranda CL;Lowry MB;Hsu VL;Lohr CV;Wong CP;Jump DB;Robinson MM;Sharpton TJ;Maier CS;Stevens JF;Gombart AF
- 通讯作者:Gombart AF
Xanthohumol Requires the Intestinal Microbiota to Improve Glucose Metabolism in Diet-Induced Obese Mice.
- DOI:10.1002/mnfr.202100389
- 发表时间:2021-11
- 期刊:
- 影响因子:5.2
- 作者:Logan IE;Shulzhenko N;Sharpton TJ;Bobe G;Liu K;Nuss S;Jones ML;Miranda CL;Vasquez-Perez S;Pennington JM;Leonard SW;Choi J;Wu W;Gurung M;Kim JP;Lowry MB;Morgun A;Maier CS;Stevens JF;Gombart AF
- 通讯作者:Gombart AF
Phytochemical characterization of Tabernanthe iboga root bark and its effects on dysfunctional metabolism and cognitive performance in high-fat-fed C57BL/6J mice.
- DOI:10.31665/jfb.2018.3154
- 发表时间:2018-09-01
- 期刊:
- 影响因子:0
- 作者:Bading-Taika, Bayissi;Akinyeke, Tunde;Stevens, Jan F
- 通讯作者:Stevens, Jan F
Plasma metabolomics supports the use of long-duration cardiac arrest rodent model to study human disease by demonstrating similar metabolic alterations.
- DOI:10.1038/s41598-020-76401-x
- 发表时间:2020-11-12
- 期刊:
- 影响因子:4.6
- 作者:Shoaib M;Choudhary RC;Choi J;Kim N;Hayashida K;Yagi T;Yin T;Nishikimi M;Stevens JF;Becker LB;Kim J
- 通讯作者:Kim J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jan Frederik Stevens其他文献
Correction to: Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial
- DOI:
10.1186/s13063-020-04834-w - 发表时间:
2020-10-26 - 期刊:
- 影响因子:2.000
- 作者:
Ryan Bradley;Blake O. Langley;Jennifer J. Ryan;John Phipps;Douglas A. Hanes;Emily Stack;Janet K. Jansson;Thomas O. Metz;Jan Frederik Stevens - 通讯作者:
Jan Frederik Stevens
Antiobesogenic Potential of Seaweed Dulse (Palmaria palmata) in High-fat Fed C57BL/6 J Mice (P21-014-19)
- DOI:
10.1093/cdn/nzz041.p21-014-19 - 发表时间:
2019-06-01 - 期刊:
- 影响因子:
- 作者:
Rufa Mendez;Cristobal Miranda;Courtney Armour;Thomas Sharpton;Jan Frederik Stevens;Jung Kwon - 通讯作者:
Jung Kwon
Hop polyphenols for mitigating metabolic syndrome
蛇麻草多酚对代谢综合征的缓解作用
- DOI:
10.1016/j.freeradbiomed.2022.06.020 - 发表时间:
2022-08-20 - 期刊:
- 影响因子:8.200
- 作者:
Jan Frederik Stevens - 通讯作者:
Jan Frederik Stevens
Jan Frederik Stevens的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jan Frederik Stevens', 18)}}的其他基金
Computation-assisted discovery of bioactive minor cannabinoids from hemp
计算辅助从大麻中发现生物活性次要大麻素
- 批准号:
10791213 - 财政年份:2023
- 资助金额:
$ 48.44万 - 项目类别:
Ascorbylation of Oxidized Lipids and Atherosclerosis
氧化脂质的抗坏血酸与动脉粥样硬化
- 批准号:
7230442 - 财政年份:2006
- 资助金额:
$ 48.44万 - 项目类别:
HYBRID TRIPLE QUADRUPOLE LINEAR ION TRAP MASS SPECTROMETER
混合三重四极杆线性离子阱质谱仪
- 批准号:
7335272 - 财政年份:2006
- 资助金额:
$ 48.44万 - 项目类别:
Hybrid triple quadrupole linear ion trap mass spectrometer
混合三重四极杆线性离子阱质谱仪
- 批准号:
7047369 - 财政年份:2006
- 资助金额:
$ 48.44万 - 项目类别:
Ascorbylation of Oxidized Lipids and Atherosclerosis
氧化脂质的抗坏血酸与动脉粥样硬化
- 批准号:
7619615 - 财政年份:2006
- 资助金额:
$ 48.44万 - 项目类别:
Ascorbylation of Oxidized Lipids and Atherosclerosis
氧化脂质的抗坏血酸与动脉粥样硬化
- 批准号:
7094437 - 财政年份:2006
- 资助金额:
$ 48.44万 - 项目类别:
HYBRID TRIPLE QUADRUPOLE LINEAR ION TRAP MASS SPECTROMETER: CARDIOVASCULAR
混合三重四极杆线性离子阱质谱仪:心血管
- 批准号:
7335270 - 财政年份:2006
- 资助金额:
$ 48.44万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 48.44万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 48.44万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 48.44万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 48.44万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 48.44万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 48.44万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 48.44万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 48.44万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 48.44万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 48.44万 - 项目类别: